Workvivo by Zoom is named preferred migration partner for Workplace from Meta

Meta is discontinuing Workplace and will partner with Workvivo to assist with customer transitions.

SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) — Today, Workvivo by Zoom was named Meta’s only preferred migration partner for its customers as it retires Workplace from Meta.

Meta is discontinuing Workplace from Meta – its employee engagement platform. To assist with customer transitions, Meta will partner with Workvivo as its only preferred migration partner.

Workplace from Meta and Workvivo plan to provide migration tools for customers migrating to Workvivo and Workvivo will also offer additional implementation services at no further cost to support customers’ transition.

Workplace from Meta customers can find more information about migrating to Workvivo here.

John Goulding, CEO and founder of Workvivo, said: “We know that the news today may be disruptive for Workplace from Meta customers, but we’re so excited about the opportunity to support and help them. Meta has made a huge impact in this market, and we believe that Workvivo is the natural choice for Workplace from Meta customers to transition their employee experience platform.

“It’s our top priority to support customers through this transition, and our team is working to make this process as frictionless as possible. We put our customers first, and this will be no different for the Workplace from Meta customers. We are excited to welcome Workplace from Meta customers into our incredible customer community and see the amazing things they can do with Workvivo.”

Eric S. Yuan, CEO and founder of Zoom said: “Since Workvivo joined the Zoom family, we’ve seen how powerful this platform is at engaging workforces and bringing culture to life – especially for frontline employees who may not have a desk or even an email address. Workvivo has seen momentous growth as organizations around the world are increasingly prioritizing the employee experience. We are excited to support Workplace from Meta’s customers and help them reach their goals of reaching and engaging employees – whether they’re desk or frontline workers.”

Workvivo by Zoom is the employee experience platform that simplifies communication and increases engagement by empowering employees to be heard and helping everyone feel included, no matter where they work.

Acquired by Zoom in 2023, Workvivo extends the Zoom Workplace platform to offer its customers new ways to keep employees informed, engaged, and connected. Workvivo is working with some of the world’s best-known brands to help them boost employee engagement and bring their culture to life digitally, including Dollar General, the Virgin Group, Bupa, Ryanair, Lululemon and Amazon.

About Workvivo by Zoom

Workvivo is an employee experience platform that simplifies communication and increases engagement by empowering employees to be heard and helping everyone feel included, no matter where they work. The platform unifies employee communications, engagement, intranet, and measurement features into one modern employee app that captures the heartbeat of the organization and brings its culture to life.

Founded in 2017, Workvivo has seen momentous growth, which led to its acquisition by Zoom in 2023. Workvivo powers the employee experience at companies all over the world across all industries, including Amazon, Motherson, White Castle, Bupa and Ryanair. Workvivo regularly tops software review sites, including Gartner Digital, with a #1 spot on G2 for internal communications, intranet and engagement tool categories. For more information, visit www.workvivo.com.

Public Relations
Eleanor O’Mahony
eleanor.omahony@zoom.us

GlobeNewswire Distribution ID 9117415

En pleine transformation stratégique, le King Faisal Specialist Hospital and Research Centre accueille un nouveau directeur général adjoint

RIYAD, Arabie saoudite, 14 mai 2024 (GLOBE NEWSWIRE) — L’hôpital spécialisé et centre de recherche King Faisal, ou KFSH&RC pour King Faisal Specialist Hospital and Research Centre a récemment accueilli le Dr Björn Zoéga en tant que directeur général adjoint. Cette nomination souligne son engagement en faveur de la promotion et du maintien de l’excellence en matière de santé. Le Dr Zoéga, réputé pour sa vaste expérience en gestion et sa maîtrise des politiques de la santé, rejoint une équipe dédiée à l’heure où l’hôpital continue de piloter des initiatives stratégiques clés.

Le KFSH&RC, leader de la recherche médicale et des services cliniques, continue d’attirer des ressources expertes à l’échelle mondiale pour renforcer sa mission d’excellence en matière de santé. L’arrivée du Dr Zoéga fait avancer la stratégie de transformation numérique de l’hôpital, conçue pour doper son efficacité opérationnelle et améliorer les soins prodigués aux patients. Son expertise dans la promotion de collaborations internationales, comme en témoigne son ancien rôle de président de l’Alliance des hôpitaux universitaires européens (ou « EUHA » pour European University Hospital Alliance) et sa participation à des initiatives telles que JOIN4ATMP, visant à promouvoir l’accès à des thérapies innovantes, concourent à un meilleur alignement des services du KFSH&RC sur les tendances mondiales en matière de santé.

Les projets clés de l’hôpital prévoient le déploiement de technologies numériques avancées pour standardiser les mécanismes propres aux soins prodigués aux patients, l’adoption de nouveaux modèles de soins et la modernisation de ses installations. Ces efforts stratégiques visent à améliorer l’accès aux services médicaux et à induire une meilleure communication à leur propos, et traduisent l’engagement du KFSH&RC envers l’établissement de nouvelles normes en matière de santé.

Les précédentes contributions du Dr Zoéga à l’hôpital universitaire Karolinska, placé au deuxième rang européen et au septième rang mondial du classement 2024 des meilleurs hôpitaux du monde établi par Newsweek, ont joué en faveur d’une culture d’apprentissage continu et de collaboration entre les professionnels de santé. Elles répondent ainsi parfaitement aux objectifs du KFSH&RC. Son rôle dans la promotion de programmes comme EUCARE et sa participation au développement des échanges intra Europe d’infirmières en soins intensifs en période de crise a considérablement renforcé le développement du personnel et appuyé l’objectif de son précédent hôpital d’attirer les meilleurs talents ; un principe reflété dans le parcours de transformation du KFSH&RC. Maintenant que le Dr Zoéga prend part au leadership du KFSH&RC, l’établissement s’apprête à renforcer son rôle d’acteur clé dans le façonnage de la santé de demain en Arabie saoudite.

À propos du King Faisal Specialist Hospital and Research Centre :

Le King Faisal Specialist Hospital & Research Centre fait partie des leaders mondiaux en matière de soins de santé spécialisés, et d’innovation, servant de centre de formation et de recherche médicale avancée. Grâce à des partenariats stratégiques avec d’éminents établissements locaux, régionaux et internationaux, l’hôpital se consacre à l’avancement des technologies médicales et à l’élévation des normes de soins de santé dans le monde entier.

L’hôpital a conforté sa position de leader du secteur de la santé en Arabie saoudite et au Moyen-Orient, en se voyant décerner, pour la deuxième année consécutive, le titre de marque de santé la plus valorisée. Il se classe 9e du royaume et 28e au Moyen-Orient. L’hôpital se distingue en étant le seul hôpital du monde à figurer au top 10 des marques de son pays, comme le soulignent deux rapports de « Brand Finance » consacrés aux 50 meilleures marques d’Arabie saoudite et aux 150 meilleures marques du Moyen-Orient en 2024.

En raison des programmes de transformation et du projet royal « Saudi Vision 2030 » initié par Son Altesse Royale le Prince Héritier et Premier Ministre — que Dieu le préserve — pour renforcer le leadership du royaume dans le secteur de la santé mondiale, le KFSH&RC est devenu un centre médical universitaire de première importance dans la région MENA. En 2024, il s’est classé au 20e rang mondial pour la deuxième année consécutive selon « Brand Finance », et s’est également distingué parmi les 250 meilleurs hôpitaux du monde selon le magazine américain « Newsweek » cette même année.

Pour tout complément d’information, veuillez contacter :

M. Essam AlZahrani, Responsable des affaires médiatiques, 0555254429

M. Abdullah Alown, Coordinateur médias, 0556294232

Une photo accompagnant ce communiqué est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/83d04605-9a75-41cb-8947-81c858209621

GlobeNewswire Distribution ID 9117305

King Faisal Specialist Hospital and Research Centre Dá as Boas-Vindas ao Novo CEO Interino Durante Suas Transformações Estratégicas

RIADE, Arábia Saudita, May 14, 2024 (GLOBE NEWSWIRE) — O King Faisal Specialist Hospital and Research Centre (KFSH&RC) nomeou recentemente o Dr. Björn Zoéga como CEO Interino, confirmando o seu empenho em promover e incentivar a excelência no cuidado da saúde. O Dr. Zoéga, conhecido por sua vasta experiência em gestão e políticas de saúde, se une a uma equipe dedicada em um momento em que o hospital continua a impulsionar iniciativas estratégicas importantes.

O KFSH&RC, líder em pesquisa médica e serviços clínicos, continua a atrair experiência global para reforçar sua visão de excelência em saúde. Com o envolvimento do Dr. Zoéga, o hospital dá seguimento à sua estratégia de transformação digital que visa aprimorar a eficiência operacional e aperfeiçoar o atendimento ao paciente. Sua experiência na promoção de colaborações internacionais, evidenciada no seu antigo cargo de presidente da European University Hospital Alliance (EUHA) e com as iniciativas como a Join4ATMP, que visa promover o acesso a terapias inovadoras, alinha ainda mais os serviços do KFSH&RC às tendências globais de saúde.

Os principais projetos do KFSH&RC incluem a implantação de tecnologias digitais avançadas para agilizar o processo de atendimento ao paciente, adoção de modelos de atendimento inovadores e atualização das instalações. Esses esforços estratégicos visam aumentar o acesso aos serviços médicos e facilitar uma melhor comunicação, refletindo a dedicação do KFSH&RC em estabelecer novos padrões de saúde.

As contribuições anteriores do Dr. Zoéga no Karolinska University Hospital, que é o segundo melhor da Europa e o sétimo do mundo de acordo com o 2024 World’s Best Hospitals da revista Newsweek, onde ele cultivou uma cultura de aprendizagem contínua e colaboração entre profissionais de saúde, alinham-se bem com os objetivos do KFSH&RC. O seu papel na promoção de programas como o EUCARE e na facilitação do intercâmbio de enfermeiros de cuidados intensivos em toda a Europa durante crises melhorou significativamente o desenvolvimento do pessoal e apoiou o objetivo do seu hospital anterior de atrair os melhores talentos – um princípio espelhado na jornada de transformação do KFSH&RC. Com o Dr. Zoéga contribuindo para a liderança, o KFSH&RC está pronto para promover seu papel como ator fundamental na formação do futuro dos cuidados de saúde na Arábia Saudita.

Sobre o King Faisal Specialist Hospital and Research Centre :

O King Faisal Specialist Hospital & Research Centre é dos líderes globais de prestação de cuidados de saúde especializados, condução de inovação, e um hubs avançado de pesquisa e educação médica. Por meio de parcerias estratégicas com proeminentes instituições locais, regionais e internacionais, o hospital se dedica ao avanço de tecnologias médicas e elevação dos padrões de cuidado da saúde em todo o mundo.

O hospital conquistou sua posição como marca líder no setor de saúde em todo o Reino e Oriente Médio, marcando seu segundo ano consecutivo como a marca de saúde mais valiosa. Ele ocupa o 9º lugar no Reino e o 28º no Oriente Médio. O hospital se distingue como o único hospital do mundo a ser listado entre as 10 principais marcas do seu país, de acordo com dois relatórios da “Brand Finance” sobre as 50 marcas mais valiosas da Arábia Saudita e as 150 marcas mais valiosas do Oriente Médio em 2024.

Devido aos programas de transformação e à Vision 2030 do Reino, lançados por Sua Alteza Real o Príncipe Herdeiro e pelo Primeiro-Ministro – que Deus o proteja – para aumentar a liderança do Reino no setor global de saúde, o KFSH&RC surgiu como um dos principais Centros Médicos Acadêmicos do Oriente Médio e da África. Ele permaneceu em 20º lugar no mundo pelo segundo ano consecutivo em 2024, de acordo com o “Brand Finance”. Além disso, ele foi classificado entre os melhores hospitais do mundo em 2024 pela revista americana “Newsweek”.

Para mais informações, contate:

Sr. Essam AlZahrani, Dirigente Interino de Assuntos de Mídia, 0555254429

Sr. Abdullah Alown, Editor Sênior de Mídia, 0556294232

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/83d04605-9a75-41cb-8947-81c858209621

GlobeNewswire Distribution ID 9117305

MedSource Labs Announces Innovation in Safety, Accuracy and Functionality of IV Catheters

MedSource Labs Unveils ClearSafe Comfort® and TrueSafe Comfort® Blood Control Safety IV Catheters to protect medical staff and patients

[Minneapolis, Minnesota, Chanhassen], May 14, 2024 (GLOBE NEWSWIRE) — MedSource Labs moves the needle in the peripheral safety IV market with the announcement of ClearSafe Comfort and TrueSafe Comfort Blood Control IV Catheters with groundbreaking active blood control check valve technology.

ClearSafe Comfort and TrueSafe Comfort Blood Control IV catheters provide significant benefits over other IV catheters.

  1. Safety: A new blood control device to significantly reduce the risk of exposure to bloodborne pathogens to the caregiver and patient.
  2. Precision: A translucent flashback chamber confirms vessel entry and ensures accuracy.
  3. Front-line functionality: The ergonomic design and non-slip grip ensure easy handling for healthcare workers.

 

“Healthcare professionals subject themselves to the risks associated with needlestick injuries and exposure to bloodborne pathogens every time they access a vein,” said Dave Kunelius, President at MedSource Labs. “ClearSafe Comfort and TrueSafe Comfort Blood Control Safety IV Catheters have been engineered to minimize these risks, allowing medical staff to better serve their patients without distraction or worry.”

These devices conform to the U.S. Needlestick Safety and Prevention Act.

MedSource Labs is a leading medical product developer and supplier specializing in high-quality products and innovative medical product development. The ClearSafe Comfort and TrueSafe Comfort Blood Control Safety IV Catheters are part of MedSource Labs’ high-performing IV catheter lines focused on caring for the caregiver. See the TrueSafe Animations and ClearSafe Animations for a detailed view.

“Quality has always been a key component of our IV catheter products, and the ClearSafe Comfort and TrueSafe Comfort blood control products raise the bar for medical staff safety and patient care,” said Kunelius.

MedSource Labs is ISO 13485:2016 certified for quality management in medical device manufacturing, registered with the FDA, and the blood control catheters are 510(k) Cleared Products.

ABOUT MEDSOURCE LABS

MedSource Labs is a leading provider of quality medical products, specializing in high-quality products, equipment and innovative class II medical product development. For over two decades, MedSource Labs has been a trusted provider of quality medical products at a superb value. Recently, MedSource Labs has expanded into new markets and grown its international services and offerings, including a focus on the EMERGE product imagine/design/build process.

Attachment

Jeremy Belloit
MedSource Labs
(952) 472-0131
jbelloit@medsourcelabs.com

GlobeNewswire Distribution ID 9116905

King Faisal Specialist Hospital and Research Centre Welcomes New Deputy CEO Amid Strategic Transformations

King Faisal Specialist Hospital and Research Centre Welcomes New Deputy CEO Amid Strategic Transformations
King Faisal Specialist Hospital and Research Centre Welcomes New Deputy CEO Amid Strategic Transformations

King Faisal Specialist Hospital and Research Centre Welcomes New Deputy CEO Amid Strategic Transformations

RIYADH, Saudi Arabia, May 13, 2024 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital and Research Centre (KFSH&RC) has recently welcomed Dr. Björn Zoéga as its Deputy CEO, an appointment that underscores its commitment to promoting and fostering healthcare excellence. Dr. Zoéga, renowned for his extensive experience in healthcare management and policy, joins a dedicated team as the hospital continues to drive key strategic initiatives.

KFSH&RC, a leader in medical research and clinical services, continues to attract global expertise to bolster its vision of healthcare excellence. With Dr. Zoéga’s involvement, the hospital is advancing a digital transformation strategy designed to improve operational efficiency and enhance patient care. His expertise in fostering international collaborations, evidenced by his former role as president of the European University Hospital Alliance (EUHA) and through initiatives like JOIN4ATMP aimed at advancing access to innovative therapies, further aligns KFSH&RC’s services with global healthcare trends.

Key projects at KFSH&RC include the deployment of advanced digital technologies to streamline the patient care process, the adoption of innovative care models, and the upgrading of facility amenities. These strategic efforts aim to improve access to medical services and facilitate better communication, reflecting KFSH&RC’s dedication to setting new standards in healthcare.

Dr. Zoéga’s previous contributions at Karolinska University Hospital, which is ranked the second best in Europe and seventh globally by Newsweek’s 2024 World’s Best Hospitals, where he nurtured a culture of continuous learning and collaboration among healthcare professionals, align well with KFSH&RC’s objectives. His role in fostering programs like EUCARE and facilitating the Europe-wide exchange of intensive care nurses during crises has significantly enhanced staff development and supported his previous hospital’s goal of attracting top talent—a principle mirrored in KFSH&RC’s transformation journey. With Dr. Zoéga contributing to leadership, KFSH&RC is poised to further its role as a pivotal player in shaping the future of healthcare in Saudi Arabia.

About King Faisal Specialist Hospital and Research Centre:

King Faisal Specialist Hospital & Research Centre stands among the global leaders in providing specialized healthcare, driving innovation, and serving as an advanced medical research and education hub. Through strategic partnerships with prominent local, regional, and international institutions, the hospital is dedicated to advancing medical technologies and elevating healthcare standards worldwide.

The hospital has secured its position as the leading brand in the healthcare sector across the Kingdom and the Middle East, marking its second consecutive year as the most valuable healthcare brand. It ranks 9th within the Kingdom and 28th in the Middle East. The hospital distinguishes itself as the sole hospital globally to break into the top 10 brands in its country, as highlighted in two reports by “Brand Finance” on the 50 most valuable brands in Saudi Arabia and the 150 most valuable brands in the Middle East in 2024.

Due to the transformation programs and the Kingdom’s Vision 2030, launched by His Royal Highness the Crown Prince and Prime Minister – may God protect him – to enhance the Kingdom’s leadership in the global healthcare sector, KFSH&RC has emerged as a leading Academic Medical Centre in the Middle East and Africa. It maintained its 20th rank globally for the second consecutive year in 2024, according to “Brand Finance.” Additionally, it has been ranked among the top 250 hospitals globally in 2024 by the American magazine “Newsweek.”

For further information, please contact:

Mr. Essam AlZahrani, Acting Head of Media Affairs, 0555254429

Mr. Abdullah Alown, Media Coordination Officer, 0556294232

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/83d04605-9a75-41cb-8947-81c858209621

GlobeNewswire Distribution ID 9116335

Impulse Dynamics Surpasses 10,000 Patients Benefiting From CCM® Therapy for Heart Failure

Milestone Highlights Transformative Symptom Management for Patients Living with Heart Failure

Marlton, NJ, May 13, 2024 (GLOBE NEWSWIRE) — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced today that it has reached a worldwide milestone by surpassing 10,000 patients having received the Optimizer® system for the treatment of moderate HF. This milestone highlights the benefit and importance of this therapy in helping patients live a full life with HF.

“I noticed positive changes since the procedure, such as not feeling cold or numb, I could walk every day and everywhere, did my regular chores and shopping, and shared activities like swimming with my daughter,” said Tracey, who received her CCM® device in 2023. “I’m no longer huffing, puffing, or gasping for air,” said Joe, another HF patient who received his CCM device in 2022. “I’m reborn ─ a whole new person ─ no longer incapacitated. My life has changed so much that we’re considering taking a trip. And my wife is ecstatic because I have my life back, and we have ours again.”

“We are deeply motivated by the patients who benefit from CCM therapy. Their progress inspires us to continuously enhance our technology, aiming to improve the lives of those suffering from heart failure,” said David Prutchi, Chief Technology Officer for Impulse Dynamics, who has worked on the development of CCM therapy since its inception.

David had the opportunity to meet one of these patients, Raynita, who was implanted with an Optimizer device this year. Raynita saw immediate improvement after starting CCM therapy and gave the following remarks on the experience: “I feel like a different person. I can do things I haven’t done in years. I am attending my granddaughter’s college graduation!”

CCM is available in 44 countries, and the technology has continued to advance, based on the needs of patients and physicians. The latest generation of the proprietary CCM technology is the Optimizer Smart Mini, which offers a rechargeable battery with 20-year battery life and a smaller size designed to make the implant procedure faster and easier for patients and physicians.

“We are committed to ongoing innovation in this important therapy that has such a clear clinical need around the world,” said Jason Spees, CEO of Impulse Dynamics. “We are also getting closer to significantly impacting the implantable cardioverter defibrillator (ICD) market with successful enrollment in our INTEGRA-D clinical trial on the CCM-D® HF System, which is the first-of-its-kind technology, combining the lifesaving benefits of an ICD with HF symptom relief through CCM therapy in one device.”

The patients statements in this Press Release represent the testimonials of their individual outcomes and may not be typical for all patients.

About the Optimizer and CCM Therapy 

The Optimizer Smart Mini system delivers CCM therapy — the company’s proprietary technology — to the heart, providing an important treatment option for the millions of patients suffering from heart failure. CCM therapy is designed to significantly improve heart contraction, allowing more oxygen-rich blood to be pushed out through the body.[1] CCM therapy is indicated to improve 6-minute hall walk, quality of life, and functional status of NYHA Class III HF patients who remain symptomatic despite guideline directed medical therapy, are not indicated for CRT, and have a left ventricular ejection fraction ranging from 25 to 45 percent.

CCM is the brand name for cardiac contractility modulation—the non-excitatory electrical pulses delivered by the implantable Optimizer device to improve heart contraction. CCM therapy sends unique electrical pulses to the heart cells during the absolute refractory period. In doing so, CCM helps the heart contract more forcibly. Impulse Dynamics has completed numerous clinical studies, including several randomized controlled trials, the results of which appeared in more than 100 articles from leading medical journals.

About Impulse Dynamics

Impulse Dynamics is dedicated to advancing the treatment of heart failure for patients and the healthcare providers who care for them. The company pioneered its proprietary CCM therapy, which uses the Optimizer technology platform to improve quality of life in HF patients. CCM therapy is delivered through the Optimizer system, which includes an implantable pulse generator (IPG) implanted in a minimally invasive procedure and approved for commercial use in the United States and 44 countries worldwide. More than 10,000 patients have received the therapy as part of clinical trials and real-world use, where it is proven to be safe and effective for heart failure patients with debilitating symptoms who otherwise have few effective options available to them. To learn more, visit www.ImpulseDynamics.com, or follow the company on LinkedIn, X (formerly Twitter), and Facebook.

Forward-looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning potential benefits of CCM therapy. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the company’s future research and development costs, capital requirements and the company’s needs for additional financing; commercial success and market acceptance of CCM therapy; the company’s ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer systems or any future products the company may seek to commercialize; competitive companies and technologies in the industry; the company’s ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the company’s business model and strategic plans for its products, technologies and business, including its implementation thereof; the company’s ability to expand, manage and maintain its direct sales and marketing organization; the company’s ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the company’s ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The company does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.


[1] European Journal of Heart Failure (2021) doi:10.1002/ejhf.2202

Attachment

Scott Way, Executive Vice President, General Counsel
Impulse Dynamics
856-434-7906
sway@impulsedynamics.com

Rohan More, Global Vice President, Marketing
Impulse Dynamics
856-642-9933
rmore@impulsedynamics.com

GlobeNewswire Distribution ID 9116301

Le KFSH&RC s’efforce d’être un pionnier dans la valorisation optimale des dépenses de santé

Le Dr Al Fayyadh à l’Université de Harvard : « Nous nous reposons sur la technologie pour relever les enjeux de santé à l’échelle mondiale »

RIYAD, Arabie saoudite, 12 mai 2024 (GLOBE NEWSWIRE) — Le Dr Majid Al Fayyadh, directeur de l’hôpital spécialisé et centre de recherche King Faisal, ou KFSH&RC pour King Faisal Specialist Hospital and Research Centre, a rejoint la conférence Gulf Creatives 2024, organisée à Harvard. L’organisation de cet événement est assurée par The Diwan, un collectif dirigé par des étudiants diplômés de la célèbre université. Dans son discours, le Dr Al Fayyadh a présenté la trajectoire du KFSH&RC depuis sa création à Riyad il y a presque cinquante ans, mettant en avant comment il est parvenu à réduire considérablement la nécessité de se rendre à l’étranger pour les patients en quête de soins médicaux. L’hôpital spécialisé et centre de recherche King Faisal est aujourd’hui un prestataire de santé de premier ordre qui propose des solutions de pointe pour le traitement des maladies cardiaques, des tumeurs, des greffes d’organes et des troubles génétiques.

Le Dr Al Fayyadh a également évoqué la transformation de l’établissement en une fondation indépendante à but non lucratif. Cette démarche, a-t-il indiqué, s’inscrit dans la vision stratégique de l’hôpital à devenir un leader mondial de l’innovation au service de la santé, en focalisant les efforts sur l’excellence, l’innovation et les investissements dans la technologie de pointe pour relever les enjeux de santé à l’échelle mondiale.

« Les instances leader du royaume ont établi un objectif clair pour le KFSH&RC, sous mandat d’un décret royal faisant converger l’hôpital en une fondation indépendante en genre propre, et à but non lucratif » explique Son Excellence le Dr Al Fayyadh.

A souligné par ailleurs que cette transformation vise à relever les normes internationales applicables aux soins de santé au profit de plus d’indépendance et de flexibilité. Cette évolution statutaire permettra au KFSH&RC d’optimiser les services existants, de poursuivre de nouvelles opportunités et d’axer ses ressources sur des initiatives jouant en faveur de la santé et du bien-être humain au sein du royaume et à l’échelle internationale. En fin de compte, cette initiative renforce l’engagement du KFSH&RC envers l’excellence centrée sur le patient.

Le Dr Al Fayyadh a observé que le KFSH&RC se considère comme un leader de la valorisation optimale des dépenses de santé, en adoptant des pratiques fondées sur des preuves aux fins de garantir les meilleurs résultats pour les patients. Il cherche à rester à l’avant-garde de l’innovation mondiale en matière de santé en pilotant des initiatives conçues pour accroître l’équité en matière de santé et l’accès aux soins dans le monde entier. À cet effet, l’hôpital poursuivra ses investissements dans des installations médicales de pointe, des outils de diagnostic avancés et des technologies de traitement de pointe. En s’appuyant sur les progrès réalisés dans des domaines tels que la thérapie cellulaire CAR T, les opérations chirurgicales robotisées, les greffes d’organes et la médecine personnalisée, l’institution aspire atteindre une compétitivité mondiale. Elle y parviendra d’autant mieux en privilégiant l’embauche d’un personnel exceptionnel, en poursuivant des percées dignes d’un prix Nobel et en renforçant les collaborations internationales stratégiques.

Le Dr Al Fayyadh a participé à une table ronde et y a souligné l’évolution du paysage de la santé et les résultats positifs issus de la transformation permanente des soins aux patients apportés par le KFSH&RC. Il a également abordé les enjeux actuels et les développements de demain qui se dessinent au sein du secteur de la santé, en insistant sur les effets prononcés des innovations de l’hôpital sur l’évolution de la santé mondiale. Enfin, le Dr Al Fayyadh a mis en lumière l’efficacité propre aux desseins de transformation de l’hôpital au double regard des objectifs du programme royal de transformation du secteur de la santé et du projet « Saudi Vision 2030 ».

Le KFSH&RC est reconnu parmi les principales institutions du monde à fournir des soins de santé spécialisés, à incarner l’innovation et à faire acte de centre de recherche médicale et d’éducation avancé. L’hôpital se consacre au développement de technologies médicales et au relèvement du niveau des soins de santé dans le monde entier, en forgeant des partenariats avec des institutions locales, régionales et internationales de premier plan pour atteindre les meilleures pratiques dans les domaines cliniques, de recherche et d’éducation.

Pour la deuxième année consécutive, le KFSH&RC a été consacré au titre de la première institution du royaume et se classe à la 20e position du classement mondial distinguant les 250 principaux centres médicaux universitaires du monde. Son empreinte est également reconnue au titre de la marque de santé la plus valorisée du royaume et du Moyen-Orient en 2024, selon Brand Finance, et le magazine Newsweek l’a classé parmi les 250 meilleurs hôpitaux du monde.

À propos de l’hôpital spécialisé et centre de recherche King Faisal :

Le King Faisal Specialist Hospital & Research Centre fait partie des leaders mondiaux en matière de soins de santé spécialisés, et d’innovation, servant de centre de formation et de recherche médicale avancée. Grâce à des partenariats stratégiques avec d’éminents établissements locaux, régionaux et internationaux, l’hôpital se consacre à l’avancement des technologies médicales et à l’élévation des normes de soins de santé dans le monde entier.

L’hôpital a conforté sa position de leader du secteur de la santé en Arabie saoudite et au Moyen-Orient, en se voyant décerner pour la deuxième année consécutive le titre de marque de santé la plus valorisée. Il se classe 9e du royaume et 28e au Moyen-Orient. L’hôpital se distingue en étant le seul hôpital du monde à figurer au top 10 des marques de son pays, comme le soulignent deux rapports de « Brand Finance » consacrés aux 50 meilleures marques d’Arabie saoudite et aux 150 meilleures marques du Moyen-Orient en 2024, respectivement.

En raison des programmes de transformation et du projet royal « Saudi Vision 2030 » initié par Son Altesse Royale le Prince Héritier et Premier Ministre – que Dieu le préserve – pour renforcer le leadership du royaume dans le secteur de la santé mondiale, le KFSH&RC est devenu un centre médical universitaire de première importance dans la région MENA. En 2024, il s’est classé au 20e rang mondial pour la deuxième année consécutive selon « Brand Finance », et s’est également distingué parmi les 250 meilleurs hôpitaux du monde selon le magazine américain « Newsweek » cette même année.

Pour tout complément d’information, veuillez contacter :

M. Essam AlZahrani, Responsable des affaires médiatiques, 0555254429

M. Abdullah Alown, Coordinateur médias, 0556294232

Les photos jointes au présent communiqué sont disponibles aux adresses suivantes :
https://www.globenewswire.com/NewsRoom/AttachmentNg/d9d0ed27-fa87-49ac-b72b-ccf5b5843637
https://www.globenewswire.com/NewsRoom/AttachmentNg/682fadee-20a5-4328-bf00-e036bc3350fd

GlobeNewswire Distribution ID 9115946

KFSH&RC Dedicado a Ser Pioneiro na Maximização do Valor dos Gastos com Saúde

Dr. Al Fayyadh em Harvard: Utilizamos a Tecnologia para Enfrentar os Desafios Globais de Saúde

RIADE, Arábia Saudita, May 12, 2024 (GLOBE NEWSWIRE) — O Dr. Majid Al Fayyadh, CEO do King Faisal Specialist Hospital and Research Centre (KFSH&RC) participa da Gulf Creatives Conference (GCC) at Harvard 2024. O evento, GCC at Harvard, é organizado pela The Diwan, uma organização dirigida por estudantes de pós-graduação da Universidade de Harvard. No seu discurso, o Dr. Al Fayyadh exibiu a jornada do KFSH&RC desde a sua criação em Riade há quase cinco décadas, mostrando como o hospital reduziu significativamente a necessidade de os pacientes viajarem para outros países para obterem cuidados médicos. O KFSH&RC passou a ser um prestador de serviços de saúde terciário de primeira linha e hoje oferece tratamentos de ponta para doenças cardíacas, tumores, transplante de órgãos e distúrbios genéticos.

O Dr. Al Fayyadh discutiu a transformação do KFSH&RC em uma fundação independente e sem fins lucrativos. Essa iniciativa, segundo ele, está alinhada com a visão estratégica da organização de se tornar líder global em inovação em saúde, enfatizando a excelência, inovação e investimento em tecnologia de ponta para enfrentar os desafios globais de saúde.

“A liderança saudita delineou uma visão clara para o KFSH&RC, estipulada por um decreto real de transição do hospital para uma fundação independente Sui Generis, sem fins lucrativos”, disse Sua Excelência, o Dr. Al Fayyadh.

Ele destacou ainda que essa transformação busca elevar os padrões globais de saúde por meio da maior independência e flexibilidade. Essa mudança permitirá que o KSFH&RC otimize os serviços existentes, busque novas oportunidades e direcione recursos para iniciativas que promovam a saúde e o bem-estar humanos dentro do Reino e no exterior. Em última análise, essa transição confirma a dedicação do KFSH&RC para com a excelência centrada no paciente.

O Dr. Al Fayyadh apontou que o KFSH&RC se vê como líder na maximização do valor dos gastos com saúde, aderindo a práticas baseadas em evidências para garantir ótimos resultados para os pacientes. O hospital busca permanecer na vanguarda da inovação global em saúde, com iniciativas destinadas a aumentar a equidade e o acesso à saúde em todo o mundo. Para conseguir isso, o KFSH&RC continuará a investir em instalações médicas de ponta, equipamentos avançados de diagnóstico, e tecnologias de tratamento de última geração. Com base no progresso existente em áreas como terapia com células CAR T, cirurgias robóticas, transplantes de órgãos e medicina personalizada, a instituição visa alcançar competitividade global. Isso será ainda mais apoiado pela promoção de uma força de trabalho excepcional, pela busca de avanços a nível do Prêmio Nobel e pelo fortalecimento de colaborações internacionais estratégicas.

O Dr. Al Fayyadh participou de um painel de discussão com foco no cenário em evolução do setor de saúde e nos resultados positivos da transformação contínua do KFSH&RC no atendimento ao paciente. Ele também abordou os desafios atuais e antecipou desenvolvimentos futuros no setor de saúde, enfatizando o profundo impacto das inovações do hospital no avanço global da saúde. Além disso, o Dr. Al Fayyadh destacou o papel eficaz das iniciativas transformadoras do hospital no alinhamento com os objetivos do Programa de Transformação do Setor de Saúde e da Saudi Vision 2030.

O KFSH&RC é reconhecido como uma das principais instituições mundiais pelo seu cuidado de saúde especializado, incentivo à inovação, sendo um hub avançado de pesquisa e educação médica avançada. Ele se dedica ao desenvolvimento de tecnologias médicas e aprimoramento dos padrões de cuidados em todo o mundo por meio de parcerias com as principais instituições locais, regionais e internacionais, para oferecer um serviço de classe mundial nos campos clínico, de pesquisa e educacional.

Pelo segundo ano consecutivo, o KFSH&RC manteve seu status de instituição líder no Reino, ocupando o 20º lugar mundial entre os 250 melhores centros médicos acadêmicos do mundo. Também foi reconhecido como a marca de saúde mais valiosa do Reino e do Oriente Médio em 2024, de acordo com a Brand Finance, e foi classificado entre os 250 melhores hospitais do mundo pela Newsweek Magazine.

Sobre o King Faisal Specialist Hospital and Research Centre :

O King Faisal Specialist Hospital & Research Centre é dos líderes globais de prestação de cuidados de saúde especializados, condução de inovação, e um hubs avançado de pesquisa e educação médica. Por meio de parcerias estratégicas com proeminentes instituições locais, regionais e internacionais, o hospital se dedica ao avanço de tecnologias médicas e elevação dos padrões de cuidado da saúde em todo o mundo.

O hospital conquistou sua posição como marca líder no setor de saúde em todo o Reino e Oriente Médio, marcando seu segundo ano consecutivo como a marca de saúde mais valiosa. Ele ocupa o 9º lugar no Reino e o 28º no Oriente Médio. O hospital se distingue como o único hospital do mundo a ser listado entre as 10 principais marcas do seu país, de acordo com dois relatórios da “Brand Finance” sobre as 50 marcas mais valiosas da Arábia Saudita e as 150 marcas mais valiosas do Oriente Médio em 2024.

Devido aos programas de transformação e à Vision 2030 do Reino, lançados por Sua Alteza Real o Príncipe Herdeiro e pelo Primeiro-Ministro – que Deus o proteja – para aumentar a liderança do Reino no setor global de saúde, o KFSH&RC surgiu como um dos principais Centros Médicos Acadêmicos do Oriente Médio e da África. Ele permaneceu em 20º lugar no mundo pelo segundo ano consecutivo em 2024, de acordo com o “Brand Finance”. Além disso, ele foi classificado entre os melhores hospitais do mundo em 2024 pela revista americana “Newsweek”.

Para mais informações, contate:

Sr. Essam AlZahrani, Dirigente Interino de Assuntos de Mídia, 0555254429

Sr. Abdullah Alown, Editor Sênior de Mídia, 0556294232

Fotos deste comunicados disponíveis em:
https://www.globenewswire.com/NewsRoom/AttachmentNg/d9d0ed27-fa87-49ac-b72b-ccf5b5843637
https://www.globenewswire.com/NewsRoom/AttachmentNg/682fadee-20a5-4328-bf00-e036bc3350fd


GlobeNewswire Distribution ID 9115946

KFSH&RC Amplia o Horizonte com um Ano de Conquistas em Três Centros de Excelência

KFSH&RC Amplia o Horizonte com um Ano de Conquistas em Três Centros de Excelência

KFSH&RC Amplia o Horizonte com um Ano de Conquistas em Três Centros de Excelência

RIADE, Arábia Saudita, May 11, 2024 (GLOBE NEWSWIRE) — O King Faisal Specialist Hospital& Research Centre (KFSH&RC) teve um ano extraordinário nos seus três Centros de Excelência—Oncologia, Genômica e Transplante.

O Centro de Excelência em Oncologia do KFSH&RC continua a liderar a luta contra a doença no Reino. Somente neste ano, o centro tratou 25% de todos os casos de câncer da Arábia Saudita, alcançando uma taxa de recuperação geral de 50% é até de 90% em casos de leucemia. Com quase cinco décadas de serviço, o compromisso do centro em fornecer tratamentos avançados contra o câncer é evidente na adoção de tecnologias como a terapia com células T CAR e a biópsia líquida, que fornecem alternativas menos invasivas aos métodos tradicionais, juntamente com transplantes extensivos de medula óssea e técnicas revolucionárias como a Quimioterapia Intraperitoneal Hipertérmica (HIPEC).

Notavelmente, o KFSH&RC alcançou um marco ao concluir mais de 100 procedimentos de terapia com células CAR T, um novo tratamento que modifica geneticamente as células imunes de um paciente para combater o câncer. Essa conquista a coloca a par com instituições renomadas que também estão avançando na terapia com células CAR-T para vários tipos de câncer no sangue e explorando aplicações expandidas por meio de ensaios clínicos e novos protocolos de tratamento. Além disso, o foco do centro em oncologia pediátrica possui uma taxa de sobrevivência de 97% em cinco anos para tumores renais e uma taxa de sobrevivência de 92% para leucemia linfoblástica aguda em crianças.

Com os rápidos avanços na medicina genômica, o KFSH&RC está adotando tecnologias de sequenciamento de última geração no atendimento ao paciente no seu Centro Genômico, revolucionando as abordagens locais e regionais para o gerenciamento de doenças. A descoberta do KFSH&RC da cepa bacteriana Stenotrophomonas Riyadhensis, facilitada pela tecnologia de sequenciamento de genoma total (WGS), contribuiu para nossa compreensão dos mecanismos de resistência a antibióticos bacterianos. Com 15.698 consultas de pacientes e mais de 5.658 genomas concluídos em 2023, o centro garante que a prevenção, o diagnóstico e o tratamento sejam precisos e personalizados.

O Centro de Excelência em Transplantes de Órgãos (OTCoE) do KFSH&RC continua a ser o principal contribuinte para as atividades de transplante de órgãos no Reino, sendo responsável por 65% de todos os transplantes realizados nacionalmente. Em 2023, o OTCoE realizou 1.092 transplantes de órgãos sólidos, incluindo o primeiro transplante de fígado totalmente robótico do mundo – onde os médicos empregaram tecnologia robótica para realizar cirurgias em pacientes e doadores — uma conquista que coloca o centro na vanguarda das práticas globais de transplante.

À medida que o KFSH&RC continua a expandir os limites do que é possível na ciência médica, seus esforços não apenas inspiram, mas também impactam significativamente a comunidade global de saúde, reafirmando seu papel como líder em inovação médica e cuidados de saúde especializados.

Sobre o King Faisal Specialist Hospital & Research Centre (KFSH&RC):

O King Faisal Specialist Hospital & Research Centre (KFSH&RC) é uma instituição de saúde líder no Oriente Médio, idealizada para ser a escolha ideal para todos os pacientes que procuram cuidados de saúde especializados. O hospital tem uma longa história de tratamento de câncer, doença cardiovascular, transplante de órgãos, neurociências e genética.

Em 2024, o “Brand Finance” classificou o King Faisal Specialist Hospital & Research Centre como o melhor centro médico acadêmico do Oriente Médio e da África e entre os 20 melhores do mundo pelo segundo ano consecutivo. Além disso, em 2024 ele foi reconhecido como um dos principais provedores de cuidado de saúde pela revista Newsweek.

Como parte da Saudi Vision 2030, um decreto real foi emitido em 21 de dezembro de 2021 visando transformar o hospital em uma entidade independente, sem fins lucrativos e de propriedade do governo, abrindo caminho para um programa abrangente de transformação com objetivo de alcançar a liderança global em cuidados de saúde por meio da excelência e inovação.

INFORMAÇÃO DE CONTATO:

Para mais informações, contate:

Sr. Essam Al-Zahrani, Dirigente Interino de Assuntos de Mídia, 0555254429

Sr. Abdullah Al-Awn, Editor Sênior de Mídia, 0556294232

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/e99afd2f-d5c6-400e-9290-26b36a580bee/pt

GlobeNewswire Distribution ID 9115847

KFSH&RC Amplia o Horizonte com um Ano de Conquistas em Três Centros de Excelência

KFSH&RC Amplia o Horizonte com um Ano de Conquistas em Três Centros de Excelência

KFSH&RC Amplia o Horizonte com um Ano de Conquistas em Três Centros de Excelência

RIADE, Arábia Saudita, May 11, 2024 (GLOBE NEWSWIRE) — O King Faisal Specialist Hospital& Research Centre (KFSH&RC) teve um ano extraordinário nos seus três Centros de Excelência—Oncologia, Genômica e Transplante.

O Centro de Excelência em Oncologia do KFSH&RC continua a liderar a luta contra a doença no Reino. Somente neste ano, o centro tratou 25% de todos os casos de câncer da Arábia Saudita, alcançando uma taxa de recuperação geral de 50% é até de 90% em casos de leucemia. Com quase cinco décadas de serviço, o compromisso do centro em fornecer tratamentos avançados contra o câncer é evidente na adoção de tecnologias como a terapia com células T CAR e a biópsia líquida, que fornecem alternativas menos invasivas aos métodos tradicionais, juntamente com transplantes extensivos de medula óssea e técnicas revolucionárias como a Quimioterapia Intraperitoneal Hipertérmica (HIPEC).

Notavelmente, o KFSH&RC alcançou um marco ao concluir mais de 100 procedimentos de terapia com células CAR T, um novo tratamento que modifica geneticamente as células imunes de um paciente para combater o câncer. Essa conquista a coloca a par com instituições renomadas que também estão avançando na terapia com células CAR-T para vários tipos de câncer no sangue e explorando aplicações expandidas por meio de ensaios clínicos e novos protocolos de tratamento. Além disso, o foco do centro em oncologia pediátrica possui uma taxa de sobrevivência de 97% em cinco anos para tumores renais e uma taxa de sobrevivência de 92% para leucemia linfoblástica aguda em crianças.

Com os rápidos avanços na medicina genômica, o KFSH&RC está adotando tecnologias de sequenciamento de última geração no atendimento ao paciente no seu Centro Genômico, revolucionando as abordagens locais e regionais para o gerenciamento de doenças. A descoberta do KFSH&RC da cepa bacteriana Stenotrophomonas Riyadhensis, facilitada pela tecnologia de sequenciamento de genoma total (WGS), contribuiu para nossa compreensão dos mecanismos de resistência a antibióticos bacterianos. Com 15.698 consultas de pacientes e mais de 5.658 genomas concluídos em 2023, o centro garante que a prevenção, o diagnóstico e o tratamento sejam precisos e personalizados.

O Centro de Excelência em Transplantes de Órgãos (OTCoE) do KFSH&RC continua a ser o principal contribuinte para as atividades de transplante de órgãos no Reino, sendo responsável por 65% de todos os transplantes realizados nacionalmente. Em 2023, o OTCoE realizou 1.092 transplantes de órgãos sólidos, incluindo o primeiro transplante de fígado totalmente robótico do mundo – onde os médicos empregaram tecnologia robótica para realizar cirurgias em pacientes e doadores — uma conquista que coloca o centro na vanguarda das práticas globais de transplante.

À medida que o KFSH&RC continua a expandir os limites do que é possível na ciência médica, seus esforços não apenas inspiram, mas também impactam significativamente a comunidade global de saúde, reafirmando seu papel como líder em inovação médica e cuidados de saúde especializados.

Sobre o King Faisal Specialist Hospital & Research Centre (KFSH&RC):

O King Faisal Specialist Hospital & Research Centre (KFSH&RC) é uma instituição de saúde líder no Oriente Médio, idealizada para ser a escolha ideal para todos os pacientes que procuram cuidados de saúde especializados. O hospital tem uma longa história de tratamento de câncer, doença cardiovascular, transplante de órgãos, neurociências e genética.

Em 2024, o “Brand Finance” classificou o King Faisal Specialist Hospital & Research Centre como o melhor centro médico acadêmico do Oriente Médio e da África e entre os 20 melhores do mundo pelo segundo ano consecutivo. Além disso, em 2024 ele foi reconhecido como um dos principais provedores de cuidado de saúde pela revista Newsweek.

Como parte da Saudi Vision 2030, um decreto real foi emitido em 21 de dezembro de 2021 visando transformar o hospital em uma entidade independente, sem fins lucrativos e de propriedade do governo, abrindo caminho para um programa abrangente de transformação com objetivo de alcançar a liderança global em cuidados de saúde por meio da excelência e inovação.

INFORMAÇÃO DE CONTATO:

Para mais informações, contate:

Sr. Essam Al-Zahrani, Dirigente Interino de Assuntos de Mídia, 0555254429

Sr. Abdullah Al-Awn, Editor Sênior de Mídia, 0556294232

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/e99afd2f-d5c6-400e-9290-26b36a580bee/pt

GlobeNewswire Distribution ID 9115847

Le KFSH&RC repousse les limites et célèbre une année couronnée de succès pour trois de ses centres d’excellence

Le KFSH&RC repousse les limites et célèbre une année couronnée de succès pour trois de ses centres d’excellence
Le KFSH&RC repousse les limites et célèbre une année couronnée de succès pour trois de ses centres d’excellence

Le KFSH&RC repousse les limites et célèbre une année couronnée de succès pour trois de ses centres d’excellence

RIYAD, Arabie saoudite, 11 mai 2024 (GLOBE NEWSWIRE) — Le King Faisal Specialist Hospital & Research Centre, ci-après « KFSH&RC », soit l’hôpital spécialisé et centre de recherche King Faisal, célèbre une année de succès pour trois de ses centres d’excellence, à savoir ceux dédiés à l’oncologie, à la génomique et à la transplantation d’organes, respectivement.

Le centre d’excellence en oncologie de l’hôpital poursuit sa lutte contre la maladie dans le royaume. Rien que cette année, il a traité 25 % de l’ensemble des cas de cancer déclarés en Arabie Saoudite, et a enregistré un taux de récupération global de 50 %, porté à 90 % pour les patients atteints de leucémie. Depuis près de cinquante ans, l’engagement de ce centre à développer des traitements avancés contre le cancer est manifeste. Il se traduit notamment par le recours à des techniques telles que la thérapie cellulaire CAR T ou la biopsie liquide, solutions moins invasives que les méthodes traditionnelles, mais aussi par la pratique de larges transplantations de moelle osseuse et l’application de techniques révolutionnaires comme la chimiothérapie hyperthermique intrapéritonéale, ou CHIP.

Le KFSH&RC a notamment franchi un cap clé en appliquant plus de 100 protocoles reposant sur la thérapie cellulaire CAR T, un traitement novateur qui modifie génétiquement les cellules immunitaires du patient pour lutter contre le cancer. Cette réalisation le distingue au niveau d’institutions renommées faisant également progresser cette thérapie dans le cadre de plusieurs formes de cancer du sang, et pilotant des applications étendues au moyen d’essais cliniques et de nouveaux protocoles de traitement. De plus, le centre veille à mettre un accent particulier sur l’oncologie pédiatrique, faisant constat d’un taux de survie à cinq ans mesuré à 97 % pour les tumeurs rénales, contre 92 % pour la leucémie lymphoblastique aiguë infantile.

Du fait des avancées rapides en médecine génomique, l’hôpital adopte des technologies de séquençage appliquées aux soins aux patients de nouvelle génération dans son centre de génomique, révolutionnant toutes les approches locales ou régionales de la gestion des maladies. Sa découverte de la souche bactérienne Stenotrophomonas Riyadhensis, reposant sur l’application de la technologie de séquençage du génome entier (ou SGE), a contribué à une meilleure compréhension des mécanismes de résistance aux antibiotiques des bactéries. À l’appui de 15 698 consultations enregistrées en 2023, et plus de 5 658 séquençages du génome entier réalisés, le centre veille à la précision et à la personnalisation des actions de prévention, des diagnostics et des traitements.

Enfin, le centre d’excellence en transplantation d’organes du KFSH&RC, appelé OTCoE pour Organ Transplant Centre of Excellence continue d’incarner le principal acteur de la greffe d’organes du royaume, réalisant à lui seul 65 % de toutes les transplantations effectuées au niveau national. En 2023, l’OTCoE a réalisé 1 092 greffes d’organes solides, y compris la toute première greffe de foie entièrement robotisée du monde. Lors de cette intervention, les médecins se sont reposés sur la robotique pour opérer le patient et le donneur – une réalisation qui place le centre à l’avant-garde des pratiques mondiales en matière de transplantation.

Alors que le KFSH&RC continue de repousser les limites du possible en science médicale, ses efforts sont non seulement source d’inspiration, mais frappent également la communauté mondiale de la santé de manière sensible, ce qui confirme son rôle de leader de l’innovation médicale et des soins de santé spécialisés.

À propos de l’hôpital spécialisé et centre de recherche King Faisal (ou KFSH&RC)

L’hôpital spécialisé et centre de recherche King Faisal (ou KFSH&RC) est un établissement de soins de santé de premier plan au Moyen-Orient, conçu pour être le choix idéal de tout patient en quête de soins de santé spécialisés. L’hôpital s’enorgueillit d’une riche histoire dans le traitement des cancers, des maladies cardiovasculaires, des transplantations d’organes, des neurosciences et de la génétique.

En 2024, « Brand Finance » l’a classé en tête des centres médicaux universitaires de la région MENA, et parmi les 20 premiers au niveau mondial pour la deuxième année de suite. En outre, le magazine Newsweek l’a reconnu en 2024 comme l’un des principaux fournisseurs de soins de santé du monde.

Dans le cadre du projet « Saudi Vision 2030 », un décret royal a été publié le 21 décembre 2021, visant la transformation de l’hôpital en une structure indépendante à but non lucratif sous la tutelle du gouvernement. Cette initiative a ouvert la voie à un programme de transformation complet visant à atteindre un leadership mondial dans le domaine des soins de santé grâce à l’excellence et à l’innovation.

COORDONNÉES

Pour plus d’informations, veuillez contacter :

M. Essam Al-Zahrani, Responsable des affaires médiatiques, 0555254429

M. Abdullah Al-Awn, Coordinateur médias, 0556294232

Une photo accompagnant ce communiqué est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/e99afd2f-d5c6-400e-9290-26b36a580bee/fr

GlobeNewswire Distribution ID 9115847

KFSH&RC Strives to Pioneer in Maximizing Healthcare Spending Value

Dr. Al Fayyadh at Harvard: We Leverage Technology to Tackle Global Health Challenges

KFSH&RC Strives to Pioneer in Maximizing Healthcare Spending Value

Dr. Al Fayyadh at Harvard: We Leverage Technology to Tackle Global Health Challenges

RIYADH, Saudi Arabia, May 11, 2024 (GLOBE NEWSWIRE) — Dr. Majid Al Fayyadh, CEO of King Faisal Specialist Hospital and Research Centre (KFSH&RC) joined the Gulf Creatives Conference (GCC) at Harvard 2024. The event, GCC at Harvard, is organized by The Diwan, an organization run by graduate students at Harvard University. In his address, Dr. Al Fayyadh showcased the KFSH&RC’s journey since its inception in Riyadh almost five decades ago, highlighting how it has significantly reduced the need for patients to travel abroad for medical care. KFSH&RC has evolved into a premier provider of tertiary healthcare services and today offers cutting-edge treatments for heart diseases, tumors, organ transplantation, and genetic disorders.

Dr. Al Fayyadh discussed KFSH&RC’s transformation into an independent, non-profit foundation. This move, he indicated, aligns with the organization’s strategic vision to become a global healthcare innovation leader, emphasizing excellence, innovation, and investment in cutting-edge technology to tackle global health challenges.

KFSH&RC Strives to Pioneer in Maximizing Healthcare Spending Value

Dr. Al Fayyadh at Harvard: We Leverage Technology to Tackle Global Health Challenges

“The Saudi Leadership has outlined a clear vision for KFSH&RC, mandated by a royal decree transitioning the hospital into an independent Sui Generis, non-profit foundation,” stated His Excellency, Dr. Al Fayyadh.

He further highlighted that this transformation seeks to elevate global healthcare standards through increased independence and flexibility. This shift will allow KSFH&RC to optimize existing services, pursue new opportunities, and direct resources toward initiatives that promote human health and well-being both within the Kingdom and internationally. Ultimately, this move reinforces KFSH&RC’s dedication to patient-centered excellence.

Dr. Al Fayyadh pointed out that KFSH&RC envisions itself as a leader in maximizing the value of healthcare spending, adhering to evidence-based practices to ensure optimal patient outcomes. It seeks to remain at the forefront of global healthcare innovation, with initiatives designed to increase health equity and access worldwide. To achieve this, KFSH&RC will continue to invest in cutting-edge medical facilities, advanced diagnostic equipment, and state-of-the-art treatment technologies. Building on existing progress in areas like CAR T-cell therapy, robotic surgeries, organ transplants, and personalized medicine, the institution aims to achieve global competitiveness. This will be further supported by fostering an exceptional workforce, pursuing Nobel Prize-caliber breakthroughs, and strengthening strategic international collaborations.

KFSH&RC CEO at GCC Harvard 2

Dr. Al Fayyadh joined a panel discussion focusing on the evolving landscape of the healthcare sector and the positive outcomes of KFSH&RC’s ongoing transformation in patient care. He also addressed current challenges and anticipated future developments within the healthcare sector, emphasizing the profound impact of the hospital’s innovations on global healthcare advancement. Additionally, Dr. Al Fayyadh highlighted the effective role of the hospital’s transformative initiatives in aligning with the objectives of the Health Sector Transformation Program and Saudi Vision 2030.

KFSH&RC is recognized as one of the leading global institutions that provide specialized healthcare, drive innovation, and serve as an advanced medical research and education hub. It is dedicated to developing medical technologies and elevating healthcare standards worldwide, forging partnerships with leading local, regional, and international institutions to deliver world-class services in clinical, research, and educational domains.

For the second year running, KFSH&RC has retained its status as the leading institution in the Kingdom and ranks 20th globally among the top 250 academic medical centers worldwide. It is also recognized as the most valuable healthcare brand in the Kingdom and the Middle East in 2024, according to Brand Finance, and has been ranked among the world’s top 250 hospitals by Newsweek Magazine.

KFSH&RC CEO at GCC Harvard 1

About King Faisal Specialist Hospital and Research Centre:

King Faisal Specialist Hospital & Research Centre stands among the global leaders in providing specialized healthcare, driving innovation, and serving as an advanced medical research and education hub. Through strategic partnerships with prominent local, regional, and international institutions, the hospital is dedicated to advancing medical technologies and elevating healthcare standards worldwide.

The hospital has secured its position as the leading brand in the healthcare sector across the Kingdom and the Middle East, marking its second consecutive year as the most valuable healthcare brand. It ranks 9th within the Kingdom and 28th in the Middle East. The hospital distinguishes itself as the sole hospital globally to break into the top 10 brands in its country, as highlighted in two reports by “Brand Finance” on the 50 most valuable brands in Saudi Arabia and the 150 most valuable brands in the Middle East in 2024.

Due to the transformation programs and the Kingdom’s Vision 2030, launched by His Royal Highness the Crown Prince and Prime Minister – may God protect him – to enhance the Kingdom’s leadership in the global healthcare sector, KFSH&RC has emerged as a leading Academic Medical Centre in the Middle East and Africa. It maintained its 20th rank globally for the second consecutive year in 2024, according to “Brand Finance.” Additionally, it has been ranked among the top 250 hospitals globally in 2024 by the American magazine “Newsweek.”

For further information, please contact:

Mr. Essam AlZahrani, Acting Head of Media Affairs, 0555254429

Mr. Abdullah Alown, Media Coordination Officer, 0556294232

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/d9d0ed27-fa87-49ac-b72b-ccf5b5843637
https://www.globenewswire.com/NewsRoom/AttachmentNg/682fadee-20a5-4328-bf00-e036bc3350fd

GlobeNewswire Distribution ID 9115814